FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (VOLFI)
An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type
Sponsor: AIO-Studien-gGmbH
Listed as NCT01328171, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by AIO-Studien-gGmbH, it has been updated 11 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
May 2023 — Jul 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 6 earlier versions
-
May 2021 — May 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AIO-Studien-gGmbH
- Amgen
- ClinAssess GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Augsburg, Germany , Esslingen am Neckar, Germany , Frankfurt am Main, Germany , Georgsmarienhütte, Germany , Halle, Germany , Heilbronn, Germany , Jena, Germany , Lahr, Germany , Ludwigsburg, Germany , Mannheim, Germany and 9 more locations